AUS
NZ
UK
CA
USA
IND
_01_06_2023_13_38_29_787931.jpg)
Highlights:
- Abbott Laboratories holds a dividend yield of 1.841 per cent.
- Humana Inc. paid a quarterly dividend of US$ 0.787.
- Net earnings of Abbott Laboratories in Q3 2022 were US$ 1,435 million.
The stock market has been volatile over the past year, and every sector had to bear the brunt of a volatile market condition. The slew of economic headwinds like the fastest inflation in decades, the rising interest rate hikes and concerns over impending recession have severely affected markets.
Amid, we look at two US healthcare stocks and their performances in recent quarters:
Abbott Laboratories (NYSE:ABT)
Abbott Laboratories is a US MNC with medical devices and health care products headquarters in Abbott Park, Illinois. Abbott paid a quarterly dividend of US$ 0.51 and holds a dividend yield of 1.841 per cent.
Abbot Laboratories said that its Q3 2022 net sales fell 4.7 per cent on a reported basis and came to US$ 10.4 billion while increasing 1.3 percent on an organic basis. The company's Q3 2022 financial results also raised the full-year guidance for its earnings-per-share (EPS).
In the third quarter of 2022, the company's total operating cost and expenses were posted at US$ 8,640 million compared to US$ 8,382 million in the same period a year earlier.
The net earnings of Abbott Laboratories in Q3 2022 were US$ 1,435 million versus US$ 2,100 million in the year-ago quarter.
Humana Inc. (NYSE:HUM)
Humana is among the largest private health insurers in the US, primarily administering Medicare Advantage plans. The firm is actively involved in products around government-sponsored programs. Humana paid a quarterly dividend of US$ 0.787 per share with a dividend yield of 0.645 per cent.
Humana reported Q3 2022 earnings per diluted common share of US$ 9.39 (GAAP basis). Its adjusted EPS in the reported quarter of 2022 was US$ 6.88. The YTD 2022 EPS of the health insurer was US$ 22.16 (GAAP basis), and it was US$ 23.58 on an adjusted basis.
The GAAP revenue of the company in the third quarter of 2022 was US$ 22,799 million compared to US$ 20,697 million in the corresponding quarter in 2021.
Humana's pre-tax income (GAAP) in Q3 2022 was reported at US$ 1,297 million versus US$ 1,636 million in Q3 2021.
Source: ©Kalkine Media®; © Canva via Canva.com
Bottom line
As an investor, one needs to be wary of volatile conditions. Therefore, it would be advisable to pick stocks based on thorough market research.
